I reported previously (Nov 2016) that Israel’s Regentis was to begin Phase III trials on its GelrinC, treatment for cartilage damage in the knee. The study has now been extended to 11 US sites involving 120 patients. The GelrinC implant encourages stem cells to re-grow cartilage.

https://www.businesswire.com/news/home/20181023005469/en/Regentis-Biomaterials-Expands-SAGE-Clinical-Trial-GelrinC%E2%84%A2